$BSX

Boston Scientific ($BSX) sits at a tactical low after a sharp pullback, while analysts broadly rate the stock a Strong Buy and forward multiples look more attractive than trailing metrics. This report assesses fundamentals, valuation, risks, and near-term catalysts ahead of Q1 2026 earnings.